Danilo Vieira de Lara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Danilo Vieira de Lara has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Oliveira de Melo
Universidade Federal de São Paulo, Brasil; Universidade Federal de São Paulo, Brasil
3 shared publications - Paulo Caleb Junior Lima Santos
Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM-Unifesp)
3 shared publications - Thuane Sales Gonçalves
Universidade Federal de São Paulo (Unifesp), Escola Paulista de Medicina (EPM). São Paulo (SP), Brasil
2 shared publications Ana Flávia Chaves dos Santos
State University of Ponta Grossa, Brazil
1 shared publicationCamila Lupepsa Latyki
State University of Ponta Grossa, Brazil
1 shared publicationCarmen Belmonte
Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain
1 shared publication
Latest Publications
- 24 August 2022
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 23 (13) , 739-748
Pharmacogenetic Testing-Guided Treatment for Oncology: An Overview of Reviews
Pharmacogenetics is the relationship between an individual’s genetic variations and their response to pharmacological treatment. We conducted an overview of reviews on the use of post-treatment pha...
- 24 August 2022
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 23 (13) , 739-748
Pharmacogenetic Testing-Guided Treatment for Oncology: An Overview of Reviews
Pharmacogenetics is the relationship between an individual’s genetic variations and their response to pharmacological treatment. We conducted an overview of reviews on the use of post-treatment pha...
- 5 April 2022
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 23 (7) , 443-452
Pharmacogenetics of Clopidogrel and Warfarin in the Treatment of Cardiovascular Diseases: An Overview of Reviews
Pharmacogenetics (PGx) is the relationship between an individual's genetic variations and the response to pharmacological treatment. We chose to perform an overview of reviews on PGx testing-guided...
- 5 April 2022
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 23 (7) , 443-452
Pharmacogenetics of Clopidogrel and Warfarin in the Treatment of Cardiovascular Diseases: An Overview of Reviews
Pharmacogenetics (PGx) is the relationship between an individual's genetic variations and the response to pharmacological treatment. We chose to perform an overview of reviews on PGx testing-guided...
- 11 May 2021
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 22 (8) , 505-513
Pharmacogenetic Testing in Psychiatry and Neurology: an Overview of Reviews
Pharmacogenetic testing is available to healthcare professionals to guide drug selection and prevent adverse events. However, its implementation in the clinical practice of psychiatry/neurology sti...
- 11 May 2021
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 22 (8) , 505-513
Pharmacogenetic Testing in Psychiatry and Neurology: an Overview of Reviews
Pharmacogenetic testing is available to healthcare professionals to guide drug selection and prevent adverse events. However, its implementation in the clinical practice of psychiatry/neurology sti...
- 21 February 2019
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 33 (4) , 522-531
Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics
Agomelatine is an agonist of the melatoninergic receptors used for the treatment of depression. Our aim was to evaluate the effect of genetic polymorphisms in metabolising enzymes and the P-glycoprotein transporter on agomelatine pharmacokinetics and pharmacodynamics. Twenty-eight healthy volunteers receiving a single 25 mg oral dose of agomelatine, were genotyped for nine polymorphisms in cytochrome P450 enzymes (CYP1A2, CYP2C9 and CYP2C19) and adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1), by real-time polymerase chain reaction . Agomelatine concentrations were measured by high performance liquid chromatography coupled to a tandem mass spectrometry detector. We calculated a CYP1A2 activity score that was directly correlated with agomelatine pharmacokinetics. Individuals with a decreased enzyme activity (*1C carriers) had a lower clearance and accumulated higher concentrations of agomelatine. In contrast, individuals with a high CYP1A2 inducibility (*1F or *1B carriers) showed an extensive clearance and lower agomelatine concentrations. The apparently marked differences between races were due to the different CYP1A2 genotype distribution. CYP2C9 intermediate/poor metabolisers showed a higher area under the concentration-time curve and maximum concentration. ABCB1 G2677T/A polymorphism affected the time to reach maximum concentration, as subjects carrying A/A+A/T genotypes showed higher values. No association was found for CYP2C19 phenotype. Agomelatine did not produce any change in blood pressure, heart rate or QT interval. CYP1A2 polymorphisms affect agomelatine pharmacokinetics. CYP1A2 phenotype inferred from the genotyping of CYP1A2*1C, *1F and *1B alleles might be a potential predictor of agomelatine exposure. ABCB1 G2677T/A could affect agomelatine absorption, as subjects with A/A+A/T genotypes had lower agomelatine concentration and they take more time to reach the maximum concentration.
- 21 February 2019
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 33 (4) , 522-531
Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics
Agomelatine is an agonist of the melatoninergic receptors used for the treatment of depression. Our aim was to evaluate the effect of genetic polymorphisms in metabolising enzymes and the P-glycoprotein transporter on agomelatine pharmacokinetics and pharmacodynamics. Twenty-eight healthy volunteers receiving a single 25 mg oral dose of agomelatine, were genotyped for nine polymorphisms in cytochrome P450 enzymes (CYP1A2, CYP2C9 and CYP2C19) and adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1), by real-time polymerase chain reaction . Agomelatine concentrations were measured by high performance liquid chromatography coupled to a tandem mass spectrometry detector. We calculated a CYP1A2 activity score that was directly correlated with agomelatine pharmacokinetics. Individuals with a decreased enzyme activity (*1C carriers) had a lower clearance and accumulated higher concentrations of agomelatine. In contrast, individuals with a high CYP1A2 inducibility (*1F or *1B carriers) showed an extensive clearance and lower agomelatine concentrations. The apparently marked differences between races were due to the different CYP1A2 genotype distribution. CYP2C9 intermediate/poor metabolisers showed a higher area under the concentration-time curve and maximum concentration. ABCB1 G2677T/A polymorphism affected the time to reach maximum concentration, as subjects carrying A/A+A/T genotypes showed higher values. No association was found for CYP2C19 phenotype. Agomelatine did not produce any change in blood pressure, heart rate or QT interval. CYP1A2 polymorphisms affect agomelatine pharmacokinetics. CYP1A2 phenotype inferred from the genotyping of CYP1A2*1C, *1F and *1B alleles might be a potential predictor of agomelatine exposure. ABCB1 G2677T/A could affect agomelatine absorption, as subjects with A/A+A/T genotypes had lower agomelatine concentration and they take more time to reach the maximum concentration.
- Open Access
- 1 March 2015
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 51 (1) , 111-115
Effects of Hypericum perforatum on turning behavior in an animal model of Parkinson's disease
Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by the slow and progressive death of dopaminergic neurons in the (substantia nigra pars compact). Hypericum perforatum (H. perforatum) is a plant widely used as an antidepressant, that also presents antioxidant and anti-inflammatory properties. We evaluated the effects of H. perforatum on the turning behavior of rats submitted to a unilateral administration of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle as an animal model of PD. The animals were treated with H. perforatum (100, 200, or 400 mg/kg, v.o.) for 35 consecutive days (from the 28th day before surgery to the 7th day after). The turning behavior was evaluated at 7, 14 and 21 days after the surgery, and the turnings were counted as contralateral or ipsilateral to the lesion side. All tested doses significantly reduced the number of contralateral turns in all days of evaluation, suggesting a neuroprotective effect. However, they were not able to prevent the 6-OHDA-induced decrease of tyrosine hydroxylase expression in the lesioned striatum. We propose that H. perforatum may counteract the overexpression of dopamine receptors on the lesioned striatum as a possible mechanism for this effect. The present findings provide new evidence that H. perforatum may represent a promising therapeutic tool for PD.
- 1 March 2015
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 51 (1) , 111-115
Open AccessEffects of Hypericum perforatum on turning behavior in an animal model of Parkinson's disease
Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by the slow and progressive death of dopaminergic neurons in the (substantia nigra pars compact). Hypericum perforatum (H. perforatum) is a plant widely used as an antidepressant, that also presents antioxidant and anti-inflammatory properties. We evaluated the effects of H. perforatum on the turning behavior of rats submitted to a unilateral administration of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle as an animal model of PD. The animals were treated with H. perforatum (100, 200, or 400 mg/kg, v.o.) for 35 consecutive days (from the 28th day before surgery to the 7th day after). The turning behavior was evaluated at 7, 14 and 21 days after the surgery, and the turnings were counted as contralateral or ipsilateral to the lesion side. All tested doses significantly reduced the number of contralateral turns in all days of evaluation, suggesting a neuroprotective effect. However, they were not able to prevent the 6-OHDA-induced decrease of tyrosine hydroxylase expression in the lesioned striatum. We propose that H. perforatum may counteract the overexpression of dopamine receptors on the lesioned striatum as a possible mechanism for this effect. The present findings provide new evidence that H. perforatum may represent a promising therapeutic tool for PD.